Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PLX

STRONG BUY

Protalix BioTherapeutics, Inc. · Healthcare · United States · $191M · Avg Vol: $1M/d

99
StockRank
Get insider-trade alerts
Q
83
V
67
M
65
P/E (TTM)
12.5x
ROE
27.3%
D/E
0.1x
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →
Loading 1Y...
PRICE (1Y)+15.6%
2.022.132.232.342.44Jun 11Jul 6Jul 24
SMA 50SMA 200
Close
$2.37
RSI (14)
57.1
52W High
$3.19
From 52W High
0.7%

SCORE BREAKDOWN

Quality
83
ROIC
37.3%98.1
ROE
27.3%93.1
GP/Assets
42.0%82.1
Op. Margin
62.7%99.1
FCF/Assets
15.8%94.1
Piotroski
376.1
Int. Cover
13.5x65.0
D/E Ratio
0.13x59.6
Current Ratio
3.15x55.9
Value
67
P/E (TTM)
12.5x82.6
EV/EBITDA
7.0x83.8
P/FCF
14.7x71.5
P/B
2.8x46.6
P/S
2.5x61.4
Div Yield
—N/A
Momentum
65
52W High %
74%61.2
RS 6M
6%79.1
SMA 50/200
0.98x59.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+226%90.1
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$191M
P/E (Forward)
3.8x
Gross Margin
45.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLX are excluded.

TickerCompanyMkt CapStockRankSignal
PLXProtalix BioTherapeutics, Inc.(you)$191M99STRONG BUY
PBYIPuma Biotechnology, Inc.$406M97STRONG BUY
QTTBQ32 Bio Inc.$450M92STRONG BUY
CRMDCorMedix Inc.$617M98STRONG BUY
RIGLRigel Pharmaceuticals, Inc.$680M98STRONG BUY
NAGENiagen Bioscience, Inc.$256M73BUY
ICCCImmuCell Corporation$100M78BUY
ZVRAZevra Therapeutics, Inc.$563M81STRONG BUY
AGENAgenus Inc.$249M61HOLD
ORMPOramed Pharmaceuticals Inc.$165M58HOLD

Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.7%

Protalix BioTherapeutics, Inc. (PLX) — Stock Score Summary

Protalix BioTherapeutics, Inc. (PLX) has a MoatMap StockRank of 99/100 based on Quality (83/100), Value (67/100), and Momentum (65/100) factor scores. The current signal is STRONG BUY.

Key Financial Metrics

Price$2.37
Market Cap$191M
P/E (TTM)12.47
P/E (Forward)3.82
Price/Book2.84
Return on Equity27.3%
Return on Invested Capital37.3%
Debt/Equity0.13x
Gross Margin45.2%
Operating Margin62.7%
Revenue Growth233.7%
Free Cash Flow$13M

Protalix BioTherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Protalix BioTherapeutics, Inc.’s (PLX) StockRank?
MoatMap’s StockRank for Protalix BioTherapeutics, Inc. (PLX) is 99/100, with a Strong Buy signal. It is a composite of Quality (83), Value (67), and Momentum (65) factor ranks across MoatMap’s 20,000+ stock universe.
Does Protalix BioTherapeutics, Inc. have an economic moat?
Protalix BioTherapeutics, Inc. (PLX) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Protalix BioTherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Protalix BioTherapeutics, Inc. (PLX) is Strong Buy, based on a StockRank of 99/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Protalix BioTherapeutics, Inc. in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPLX deep dive reportAI ChampionsHow we score stocksSense-check another stock